JimJimJimJim Posted August 23, 2014 Share Posted August 23, 2014 Jim Marshall (not a doctor) said ... The Pharmaceutical Benefits Advisory Committee (PBAC) has recommended that most common chemotherapy drug for prostate cancer, Taxotere (docetaxel) be more easily available to doctors. If this recommendation is accepted by the government doctors will be able to use it when they think it is warranted using their professional judgement, without having to meet the specific rules that now apply. This would allow doctors to use docetaxel before prostate cancer becomes castrate resistant. A posting for Bruce Kynaston on this use will follow shortly. ... end Jim =============================DOCETAXEL, all forms, all strengths, all brands, Pharmaceutical Evaluation Branch, Department of Health on behalf of Actavis Pty Ltd, Hospira Pty Ltd, Sandoz Pty Ltd, Sanofi-Aventis Australia Pty Ltd and Sun Pharmaceutical Industries (Australia) Pty Ltd Change to listing (Minor submission)=============================Anti-cancer drug=============================The Department requested the PBAC consider changing the listings for docetaxel and paclitaxel from Authority required (STREAMLINED) listings to unrestricted benefit listings for all indications following the substantial price reductions that these drugs have been subject to since the PBAC’s original recommendations for listing.=============================The PBAC recommended amending the existing listings for all docetaxel and paclitaxel products from Authority required (STREAMLINED) listings to unrestricted benefit listings.============================= Link to comment Share on other sites More sharing options...
This topic is now archived and is closed to further replies.